---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-000066"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-01-02T23:59:59+00:00"
generated_at: "2026-05-16T11:49:02.874610+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA issues Complete Response Letter for Outlook Therapeutics' ONS-5010 BLA for wet AMD

## Summary
- FDA CRL states additional mechanistic/natural history data does not alter prior conclusion; confirmatory efficacy evidence needed but not defined.
- Outlook Therapeutics disagrees with decision and is exploring all available U.S. approval pathways.
- ONS-5010 (LYTENAVA) already approved in EU and UK; commercially available in Germany and UK since June 2025.
- CEO Bob Jahr reaffirms commitment to bringing first FDA-approved on-label bevacizumab for wet AMD to U.S. patients.
- Company continues to expand European presence and seek commercial partners outside Europe.

## SEC filing metadata
- accession: 0001104659-26-000066
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-01-02T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926000066/0001104659-26-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926000066/tm2534608d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-000066
- JSON: https://secwatch.observer/filing/0001104659-26-000066.json
- Plain text: https://secwatch.observer/filing/0001104659-26-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.